Nasopharyngeal Carcinoma
459
84
120
103
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
14 trials with published results (3%)
Research Maturity
103 completed trials (22% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
4.4%
20 terminated out of 459 trials
83.7%
-2.8% vs benchmark
22%
102 trials in Phase 3/4
14%
14 of 103 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 103 completed trials
Clinical Trials (459)
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC